Miripla
Also known as: SM -11355
Miplatin is a platinum anticancer drug developed by Sumitomo pharmaceutical plant Club of Japan. The specification of freeze-dried powder injection is 70mg / dose. It has a significant effect on the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. The mechanism of action is similar to other platinum drugs. It can inhibit the synthesis and replication of DNA and the growth of tumor by producing alkylation complexes and acting on DNA to form cross-linking within and between chains. Animal studies have shown that after TACE, MIPT suspension can be targeted to accumulate in tumor tissue slow-release active ingredients, which has good antitumor effect, and its antitumor activity is better than that of jingsitatin. The clinical study showed that the ratio of TeV in the two groups was 26.5% (22 / 83) and 17.9% (7 / 39), the two-year survival rates were 75.9 and 70.3%, and the three-year survival rates were 58.4% and 48.7%, respectively. Compared with jingsitatin, no hepatic vascular injury (no effect on the second treatment) was found in the group of miplatin, and the irreversible damage (adverse effect on the prognosis) to the hepatobiliary system was reduced, and the safety was better than jingsitatin. Miplatin is a kind of anticancer drug, which is soluble in the fatty acid ethyl ester of papaverine iodide oil and administered in the hepatic artery. It has a high affinity with the fatty acid ethyl ester of papaverine iodide oil, and remains in the tumor site after administration in the hepatic artery. The platinum component in the suspension can be slowly released into the blood or tissue for a long time. The bivalent platinum compound combines with DNA, and inhibits the proliferation of cancer cells by preventing DNA synthesis It improves the anti-cancer effect. Clinical trials show that the product has a good anti-cancer effect in patients who have received this treatment for the first time, or in patients who have received other treatment methods such as hepatectomy.
| Payment & Shipping Terms | Supply Capacity | ||
|---|---|---|---|
| Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
| Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
| Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Miripla
CAS 141977-79-9
Miplatin is a platinum anticancer drug developed by Sumitomo pharmaceutical plant Club of Japan. The specification of freeze-dried powder injection is 70mg / dose. It has a significant effect on the treatment of liver cancer, malignant lymphoma, non-small cell lung cancer, small cell lung cancer and superficial bladder cancer. The mechanism of action is similar to other platinum drugs. It can inhibit the synthesis and replication of DNA and the growth of tumor by producing alkylation complexes and acting on DNA to form cross-linking within and between chains. Animal studies have shown that after TACE, MIPT suspension can be targeted to accumulate in tumor tissue slow-release active ingredients, which has good antitumor effect, and its antitumor activity is better than that of jingsitatin. The clinical study showed that the ratio of TeV in the two groups was 26.5% (22 / 83) and 17.9% (7 / 39), the two-year survival rates were 75.9 and 70.3%, and the three-year survival rates were 58.4% and 48.7%, respectively. Compared with jingsitatin, no hepatic vascular injury (no effect on the second treatment) was found in the group of miplatin, and the irreversible damage (adverse effect on the prognosis) to the hepatobiliary system was reduced, and the safety was better than jingsitatin. Miplatin is a kind of anticancer drug, which is soluble in the fatty acid ethyl ester of papaverine iodide oil and administered in the hepatic artery. It has a high affinity with the fatty acid ethyl ester of papaverine iodide oil, and remains in the tumor site after administration in the hepatic artery. The platinum component in the suspension can be slowly released into the blood or tissue for a long time. The bivalent platinum compound combines with DNA, and inhibits the proliferation of cancer cells by preventing DNA synthesis It improves the anti-cancer effect. Clinical trials show that the product has a good anti-cancer effect in patients who have received this treatment for the first time, or in patients who have received other treatment methods such as hepatectomy.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
| CAS Number | 141977-79-9 |
|---|---|
| Molecular Formula | C34H68N2O4Pt |
| Place of Origin | Zhejiang,China (Mainland) |
| Brand | MOSINTER |
| Name | Miripla |
| CAS | 141977-79-9 |
Send an inquiry for Miripla
Related products
1-Bromo-3-chloro-2-methylpropane
Application:Used as pharmaceutical intermediates
1-benzyl-2-phenyl-1H-imidazole
Contact MOSINTER for product specifications and supply information.
10-Hydroxycamptothecin
Exemestane is an irreversible steroidal aromatase inhibitors, has similar structure with its substrate,natural androstenedione. And it is the pseudo substrate of aromatase . The inhibition of aromatase to estrogen deprivation is a effective method in the treatment of postmenopausal women with hormone dependent breast cancer.
2-Chlorophenothiazine
Application:Chlorpromazine hydrochloride used as drug intermediates; Pharmaceutical intermediates for the preparation of chlorpromazine, perphenazine.
3-Dimethylamino-2-methylpropyl Chloride Hydrochloride
Application:Used as pharmaceutical intermediates
3-Dimethylaminopropylchloride Hydrochloride
1. Used for synthesis of chlorpromazine, doxepin hydrochloride, chlorprothixene medicine, etc
3-Ethyl-4-methyl-3-pyrrolin-2-one
3-Ethyl-4-methyl-3-pyrrolin-2-one, a five-membered α,β-unsaturated lactam derivative, has various applications in medicinal chemistry. It can be synthesized by employing following as starting materials:[1] • allylamine, via palladium(II)-assisted cyclization • 4-methoxybenzylamine, via a ring-closing-metathesis strategy • 3-ethyl-1-(4-methoxybenzyl)-4-methyl-1,5-dihydro-2H-pyrrol-2- one
5- 1-Hydroxyl-1-methylethyl -2-propyl-imidazol-4-yl Carboxylic Acid Ethyl Ester
[5-(1-Hydroxyl-1-methylethyl)-2-propyl-imidazol-4-yl]carboxylic acid ethyl ester
